Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

905 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.
Khorashad JS, Wagner S, Greener L, Marin D, Reid A, Milojkovic D, Patel H, Willimott S, Rezvani K, Gerrard G, Loaiza S, Davis J, Goldman J, Melo J, Apperley J, Foroni L. Khorashad JS, et al. Haematologica. 2009 Jun;94(6):861-4. doi: 10.3324/haematol.2008.003715. Epub 2009 Apr 18. Haematologica. 2009. PMID: 19377081 Free PMC article.
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS. Marin D, et al. J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385986 Free PMC article.
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.
Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D. Ibrahim AR, et al. Blood. 2011 Apr 7;117(14):3733-6. doi: 10.1182/blood-2010-10-309807. Epub 2011 Feb 23. Blood. 2011. PMID: 21346253 Free PMC article.
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D. Khorashad JS, et al. Among authors: goldman jm. J Clin Oncol. 2008 Oct 10;26(29):4806-13. doi: 10.1200/JCO.2008.16.9953. Epub 2008 Jul 21. J Clin Oncol. 2008. PMID: 18645191 Free PMC article.
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J, Klammer M, Kaeda JS, Goldman JM, Apperley JF. Marin D, et al. Among authors: goldman jm. Blood. 2008 Dec 1;112(12):4437-44. doi: 10.1182/blood-2008-06-162388. Epub 2008 Aug 20. Blood. 2008. PMID: 18716134 Free PMC article.
905 results